Arcutis Biotherapeutics (ARQT) Expected to Announce Quarterly Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is projected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $60.52 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Arcutis Biotherapeutics Stock Performance

NASDAQ:ARQT opened at $13.02 on Monday. The firm’s fifty day moving average price is $13.66 and its 200 day moving average price is $11.36. Arcutis Biotherapeutics has a 1-year low of $6.99 and a 1-year high of $16.20. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.46 and a quick ratio of 2.38. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -7.27 and a beta of 1.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ARQT shares. HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Arcutis Biotherapeutics in a report on Monday, January 13th. Guggenheim reissued a “buy” rating on shares of Arcutis Biotherapeutics in a report on Monday, February 10th. Mizuho raised their target price on Arcutis Biotherapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, January 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $18.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Insider Transactions at Arcutis Biotherapeutics

In other news, Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.71, for a total transaction of $127,100.00. Following the completion of the transaction, the director now owns 141,944 shares of the company’s stock, valued at $1,804,108.24. The trade was a 6.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Masaru Matsuda sold 8,338 shares of Arcutis Biotherapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.70, for a total value of $105,892.60. Following the transaction, the insider now directly owns 178,692 shares of the company’s stock, valued at $2,269,388.40. This trade represents a 4.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,029 shares of company stock valued at $756,017 in the last 90 days. 9.50% of the stock is currently owned by insiders.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.